Moreover, SAC inactivation is common in BRCA2-deficient prostate cancer patients and many BRCA2-deficient cell lines, and PP2A inhibitors (PP2Ais) that can restore SAC activity are potential drugs for the synthetic lethality of BRCA2-mutated cancer cells. This evidence concerns the gene BRCA2 and prostate carcinoma.